Health
CAR T therapy shows long-lasting remissions in non-hodgkin lymphoma – Medical Xpress
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the…
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah, researchers in Penn’s Abramson Cancer Center reported today in the New England Journal of Medicine. The findings represent the longest follow-up published data to date for CAR T cell therapies approved by the U.S. Food and Drug Administration for the treatment of relapsed or refractory…
-
General21 hours agoCalifornia worker dead and hundreds arrested after cannabis farm raid
-
Noosa News19 hours agoUnlawful wounding charges, Caloundra – Sunshine Coast
-
General23 hours agoWallaroos fall to Black Ferns 37-12 in Wellington Test
-
General13 hours agoWest Indies-Australia live: Third day-night Test in Jamaica